Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

United States FDA Clears The REGEN Trial To Test Bioheart's Combination Gene And Stem Cell Therapy In Heart Failure Patients
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the US FDA cleared a phase I clinical trial for MyoCell SDF-1 (Stromal Derived Factor - 1) to treat congestive heart failure. The REGEN trial will enroll 15 patients in a multicenter, randomized, dose escalation study to assess the safety and cardiovascular effects of the implantation of MyoCell SDF-1 in congestive heart failure patients post myocardial infarction(s).
generic viagra online
WHO Raises Pandemic Alert To Phase 6, Director General Gives Speech
The World Health Organization (WHO) announced it has raised the level of influenza pandemic alert from phase 5 to phase 6, following an
News of the day
Denver Post Examines Efforts To Establish Needle-Exchange Programs In Colorado
The Denver Post on Friday examined efforts to establish needle-exchange programs in Colorado to reduce the risk of HIV and hepatitis C among injection drug users. According to the Post, 185 cities in Colorado have needle-exchange programs, but legislation that would have legalized needle exchanges statewide did not advance in the Legislature this year. "The issue is more complex than it perhaps first appears," Evan Dreyer, a spokesperson for Gov. Bill Ritter (D), said, adding that "law enforcement and the Colorado Department of Public Health and Environment both expressed serious reservations" about a proposal that would have legalized needle-exchanges statewide. A coalition of public health officials, treatment providers and advocates are increasing efforts to establish a needle-exchange program in Denver, the Post reports. The Denver Drug Strategy Commission in February recommended that Mayor John Hickenlooper consider a pilot needle-exchange program, DDSC Director Karla Maraccini said. The commission is looking at different programs to develop a model following Hickenlooper"s request for additional research. However, Denver District Attorney Mitch Morrissey has concerns that a local needle-exchange program would violate state law, according to Morrissey"s spokesperson Lynn Kimbrough. Eric Brown, a spokesperson for Hickenlooper, added, "Anything in contradiction to city or state law would have to be carefully considered." Proponents of needle-exchange programs say they prevent HIV and hepatitis C, but opponents say they condone injection drug use. Mark Thrun, director of HIV prevention for Denver Public Health, said, adding that needle-exchange programs prevent IDUs from "getting these chronic, potentially fatal diseases" and give public health workers "an opportunity to link them into treatment; and it lessens the economic burden on the already overburdened health care system." Thrun noted that several studies have found that needle-exchange programs do not encourage or prolong injection drug use and make IDUs more likely to seek treatment. In addition, a 2005 CDC study found that 86% of exchange programs make treatment referrals and that more than 80% offer counseling and testing for HIV/AIDS and hepatitis C.Nancy Steinfurth, executive director of the Hep C Connection, noted that an estimated 10% of HIV cases and 70% of hepatitis C cases are transmitted through needles (Auge, Denver Post, 5/15).
Cardiovascular

Daily Women's Health Policy Report Summarizes Studies Examining Ovarian Cancer

The following summarizes recent research related to ovarian cancer.~ Early periods linked to lower survival: Women who start menstruating at an early age or experience more menstrual cycles over their lifetimes appear to have a lower chance of surviving ovarian cancer, according to a study published this month in the journal Cancer Epidemiology, Biomarkers, and Prevention, Reuters reports. For the study, researcher Cheryl Robbins and colleagues analyzed the medical data of 410 ovarian cancer patients who participated in the Cancer and Steroid Hormone study between 1980 and 1982. The analysis found that the women who had their first period before age 12 had a 51% greater risk of dying than the women who began menstruating at age 14 or older. The women who had the highest number of lifetime menstrual cycles had a 67% greater risk of dying during follow-up than the women with the lowest number of cycles (Reuters, 7/24).~ Lung cancer risk higher for women after hysterectomy with ovary removal: Women who have had hysterectomies in which their uterus and both ovaries are removed to prevent ovarian cancer appear to have a higher risk for developing lung cancer, according to researchers at the University of Montreal, the New York Times reports. The researchers discovered the connection while looking for links between lung cancer and hormones for a study published in May in the International Journal of Cancer. Although they did not find a relationship between lung cancer risk and hormonal factors such as menstruation patterns, child-bearing or breastfeeding, the researchers found that women who had medically induced menopause had 1.92 times greater risk of developing lung cancer than women who had natural menopause (Caryn Rabin, New York Times, 7/24).~ Small tumors present for years before detection: Minute-sized ovarian tumors form and remain in the Fallopian tubes for an average of four years before they grow large enough to be detected, which might suggest why ovarian cancer frequently is diagnosed in its later stages, according to a study published in the journal PLoS Medicine, Reuters reports. For the study, lead researcher Patrick Brown of Stanford University and the Howard Hughes Medical Institute and colleagues analyzed the tumors of women whose Fallopian tubes and ovaries were removed because they had family histories of and genetic risk for ovarian cancer. They found small tumors -- most less than three millimeters in diameter -- that previously had not been detected in the women. In a statement, Brown said, "There is a long window of opportunity for potentially lifesaving early detection of this disease, but the tumor spreads while it is still much too small to be detected by any of the tests that have been developed or proposed to date." According to Reuters, blood tests for the compound called CA-125 may help guide therapy but do not indicate whether a woman has a tumor (Reuters, 7/28). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009